Erschienen in:
02.03.2021 | Original Article
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
verfasst von:
Felipe Alvarez-Manceñido, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Virginia Arrazubi, Raquel Hernandez, Juana M. Cano, Ana Custodio, Carles Pericay Pijaume, Gema Aguado, Nieves Martínez Lago, Manuel Sánchez Cánovas, Diego Cacho Lavin, Laura Visa, Alba Martinez-Torron, Aranzazu Arias-Martinez, Flora López, M. Luisa Limón, Rosario Vidal Tocino, Ana Fernández Montes, Maria Alsina, Paola Pimentel, Pablo Reguera, Alfonso Martín Carnicero, Avinash Ramchandani, Mónica Granja, Aitor Azkarate, Marta Martín Richard, Olbia Serra, Carolina Hernández Pérez, Alicia Hurtado, Aitziber Gil-Negrete, Tamara Sauri, Patricia Morales del Burgo, Javier Gallego
Erschienen in:
Gastric Cancer
|
Ausgabe 4/2021
Einloggen, um Zugang zu erhalten
Abstract
Background
Advanced esophageal adenocarcinoma (EAC) is generally treated similarly to advanced gastroesophageal junction (GEJ-AC) and gastric (GAC) adenocarcinomas, although GAC clinical trials rarely include EAC. This work sought to compare clinical characteristics and treatment outcomes of advanced EAC with those of GEJ-AC and GAC and examine prognostic factors.
Patients and methods
Participants comprised patients with advanced EAC, intestinal GEJ-AC, and GAC treated with platin and fluoropyrimidine (plus trastuzumab when HER2 status was positive). Overall and progression-free survival were estimated using the Kaplan–Meier method. Cox proportional hazards regression gauged the prognostic value of the AGAMENON model.
Results
Between 2008 and 2019, 971 participants from the AGAMENON-SEOM registry were recruited at 35 centers. The sample included 67.3% GAC, 13.3% GEJ-AC, and 19.4% EAC. Pulmonary metastases were most common in EAC and peritoneal metastases in GAC. Median PFS and OS were 7.7 (95% CI 7.3–8.0) and 13.9 months (12.9–14.7). There was no difference in PFS or OS between HER2− and HER2+ tumors from the three locations (p > 0.05). Five covariates were found to be prognostic for the entire sample: ECOG-PS, histological grade, number of metastatic sites, NLR, and HER2+ tumors treated with trastuzumab. In EAC, the same variables were prognostic except for grade. The favorable prognosis for HER2+ cancers treated with trastuzumab was homogenous for all three subgroups (p = 0.351) and, after adjusting for the remaining covariates, no evidence supported primary tumor localization as a prognostic factor (p = 0.331).
Conclusion
Our study supports the hypothesis that EAC exhibits clinicopathological characteristics, prognostic factors, and treatment outcomes comparable to intestinal GEJ-AC and GAC.